What is Apnimed?
Apnimed operates at the intersection of biotechnology and sleep medicine, dedicated to the discovery and development of novel oral therapies for obstructive sleep apnea. Unlike traditional mechanical interventions such as CPAP devices or surgical procedures, Apnimed's therapeutic approach targets the physiological root causes of airway collapse during sleep. This innovative pharmacological strategy aims to provide a more accessible and patient-friendly alternative for the millions of individuals suffering from OSA. As a clinical-stage entity, the firm is currently focused on validating the efficacy and safety of its pipeline, positioning itself as a disruptive force in a market historically dominated by hardware-based solutions.
How much funding has Apnimed raised?
Apnimed has raised a total of $380.3M across 6 funding rounds:
Series A
$15M
Series B
$25M
Series C
$142.3M
Debt
$23M
Private Equity
$25M
Debt
$150M
Series A (2020): $15M, investors not publicly disclosed
Series B (2021): $25M led by Seligman Investments, Morningside Venture Capital, and Tao Capital Partners , LLC
Series C (2023): $142.3M supported by Sectoral Asset Management, Morningside Venture Capital, Seligman Investments, Nexpoint Residential Trust, Tao Capital Management, and Alpha Wave Ventures
Debt (2025): $23M, investors not publicly disclosed
Private Equity (2026): $25M, investors not publicly disclosed
Debt (2026): $150M with participation from HealthCare Royalty Management
Key Investors in Apnimed
HealthCare Royalty Management
A specialized investment organization focused on providing capital solutions to the biopharmaceutical sector through royalty interest acquisitions and tailored financing.
Sectoral Asset Management
An employee-owned investment advisor specializing in global healthcare equities, with a deep focus on biotech and emerging market healthcare strategies.
Morningside Venture Capital
A private equity and venture capital firm established in 1986, known for its entrepreneurial approach and commitment to social responsibility in technology investments.
What's next for Apnimed?
Looking ahead, Apnimed is poised to utilize its recent capital injection to finalize critical clinical trials and prepare for regulatory submissions. The strategic focus will remain on the advancement of AD109, with an emphasis on demonstrating superior clinical outcomes that justify a shift in the standard of care for sleep apnea patients. Furthermore, the company is expected to leverage its strong investor network to explore potential commercial partnerships and scale its operational capabilities. As the firm moves closer to the commercialization phase, the integration of non-dilutive financing and strategic equity will be instrumental in maintaining its competitive edge and driving long-term value for stakeholders in the life sciences ecosystem.
See full Apnimed company page
